Floatz logo

Tafasitamab

B-Cell Non-Hodgkin Lymphoma

Explore 306 assets in B-Cell Non-Hodgkin Lymphoma →
Floatz Rating
B58/100
Confidence
Indicative
v0.2
Sponsor
Brown University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07502872CT.gov
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
—Not Yet Recruiting———
NCT07225439CT.gov
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
—Not Yet Recruiting———
NCT05615636CT.gov
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
—Recruiting———
NCT04882163CT.gov
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
—Withdrawn———
NCT04161248CT.gov
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · B-Cell Non-Hodgkin Lymphoma

AssetSponsorPhaseRating
Tafasitamab (this asset)Brown UniversityP2B · 58
VindesineChildren's Cancer Group, ChinaP4BBB
Anti-Cd20/Cd3 Monoclonal Antibody Regn1979University of BirminghamP3BBB
CytarabineChildren's Cancer Group, ChinaP4BBB
CamustineFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyP4BBB
ZanubrutinibThe First Affiliated Hospital of Soochow UniversityP4BBB
IsocyclophosphamideShanghai Junshi Bioscience Co., Ltd.P4BBB
Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Transduced With A Nonreplicative Self-Inactivating (Sin) Lentiviral Vector Encoding A Chimeric Antigen Receptor (Car) Consisting Of The Human Cd19-Specific Scfv, An Lgg4 Hinge Region, Cd28 Transmembrane Domain, Cd137 (4-1Bb) Co-Stimulatory Domain And Cd3 Zeta Signalling Domain, Under The Control Of A Hybrid Elongation Factor 1 Alpha (Ef1.Alpha.) And Human T Cell Leukemia Virus Type 1(Htlv-1) Regulatory Element Promoter And Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element (Wpre). The Vector Genome Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Co-Expressed With The Car And Cleaved From It By The T2A Self-Cleaving Peptide. The Vector Genome Also Contains A Splice Donor, A Fragment Of Gag, A Rev Response Element (Rre), A Mutated Central Polypurine Tract (Cppt), And A Splice AcceptorRuijin HospitalP4BBB
TacrolimusM.D. Anderson Cancer CenterP2BB

+42 more in the B-Cell Non-Hodgkin Lymphoma cohort

Other indications for Tafasitamab

IndicationSponsorPhaseRating
Diffuse Large B-Cell Lymphoma—P3B · 63
Follicular Lymphoma—P3B · 60
High Grade B-Cell Lymphoma—P2B · 59

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Tafasitamab in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/tafasitamab-b-cell-non-hodgkin-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →